Roboscreen

Roboscreen GmbH is a privately held, revenue-generating diagnostics company with over two decades of experience in developing molecular and immunochemical tests. Its core business revolves around two key areas: viral pathogen detection (Hepatitis B, C, Delta) and biomarkers for neurodegenerative diseases. Following a management buyout from Analytik Jena AG in 2020, the company operates independently but maintains strategic partnerships, holding ISO 13485 certification and distributing its products globally through a network of partners. Roboscreen actively engages in scientific collaborations and conference presentations to advance its diagnostic toolbox.

Dual-platform expertise in molecular biology (qPCR for nucleic acid detection/quantification) and immunochemistry (in-house generation of monoclonal antibodies for immunoassays). Focuses on developing assays for automated diagnostic platforms.

Roboscreen competes in specialized segments against major global IVD companies (e.g., Roche, Abbott, Siemens Healthineers) and niche biomarker firms (e.g., Quanterix, Fujirebio). Its differentiation lies in its focused R&D, dual technological expertise, and strategy as a "toolbox" provider for automated platforms, rather than a full-system vendor.